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the prospect of perspective for combinations with immu-
nomodulatory agents like checkpoint inhibitors.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
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To the Editor
Zaniboni and Formica recently published a review article 
considering preclinical and clinical data in the current con-
text of optimal therapeutic sequences in metastatic colo-
rectal cancer [1]. Their conclusions supported anti-EGFR 
agents as first-line treatment before anti-VEGF agents. 
Different biological and molecular treatment-conferred 
changes were advocated to support this order of drug com-
bination. Surprisingly, an important aspect which was not 
considered by the authors is the current reconsideration of 
anti-VEGF and anti-EGFR effects through their respective 
and complementary abilities to modulate tumor immunity 
both directly and indirectly. For instance, on the one hand, 
involvement of T cells has been reported to be a compo-
nent of the antitumor activity of EGFR-targeted monoclo-
nal antibodies [2]. Also, EGFR activation has recently been 
shown to upregulate PDL-1 [3], potentially implying that 
EGFR inhibition can restore anti-tumor immunity. On the 
other hand, apart from its pro-angiogenic effect, VEGF 
must also be considered to be a strong immunosuppres-
sor agent [4] and VEGF-targeted therapy has been shown 
very recently to combine favorably with checkpoint inhibi-
tors based on pronounced CD8+ T cells tumor infiltration 
boosted by the anti-angiogenic drug [5].
Taken all together, these different features must lead 
us to reconsider anti-VEGF and anti-EGFR combina-
tions, focusing not only on the association but also on 
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